Nasdaq and Other Hurdles
Reverse Merger Returns Vary Widely: Weighing the Risk
By Trista Morrison
Monday, July 25, 2011
With the market for initial public offerings (IPO) refusing to heat up as many had hoped, biotech companies are once again turning to reverse mergers for entry to the public markets.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.